Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült ÁllamokFázis nélkül

A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems

A legfontosabb adatok

Ki végzi
Takeda
Hol
Charleston, Gainesville és Nashville (Egyesült Államok)Mind a 3 helyszín megnézéseMég 5 másik országban, 5 helyszínen
Azonosító
Állapot
Toboroz
Résztvevők
500 fő, tervezett
Kezdés
2024. szept. 25.
Várható befejezés
2031. dec. 31.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A regiszteradat frissítve
2026. július 24.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 10 feltétel megnézéseKevesebb

Ki vehet részt

  • Participants who meet all the following criteria will be included in the study
  • Cohorts 1 and 2:
  • Willing to provide written informed consent to participate in the study
  • >=18 years of age at enrollment in this study
  • Participants with documented diagnosis of AATD, meeting the following criteria:; Cohort 1 (AATD-Pi*ZZ genotype/phenotype); Pi*ZZ genotype as documented from rapid genetic assay, sequencing, or polymerase chain reaction (PCR), or Pi*ZZ phenotype as documented from iso-electric focusing (IEF) electrophoresis; Cohort 2 (AATD-Pi*SZ genotype/phenotype with liver disease manifestation); Pi*SZ genotype as documented from rapid genetic assay, sequencing, or PCR, or Pi*SZ phenotype as documented from IEF electrophoresis, and; Moderate-advanced or severe liver disease manifestation as defined by either liver biopsy or surrogate laboratory or imaging measures

Ki nem vehet részt

  • Participants with prior participation in an interventional clinical trial evaluating liver or lung disease, or who have received an investigational AATD-directed therapy under a compassionate use program, will be excluded if they do not present one of the following:; A minimum washout period of 6 months has elapsed since the last dose of the investigational product; A history of having received placebo in prior interventional trials (to be evaluated on a case-by-case basis)
  • History of liver transplant
  • No results for either biopsies, magnetic resonance elastography (MRE), FibroScan (vibration controlled transient elastography [VCTE]), or Aspartate aminotransferase to platelet ratio index (APRI) in the 24 months prior to the index/enrollment date and has none of these tests ordered during the index period (i.e., index date +90 days)
  • Participants who meet any following criteria will be excluded from the study
  • Documented AATD genotype/phenotype other than Pi*ZZ or Pi*SZ

Helyszínek itt: Egyesült Államok

Még 5 másik országban, 5 helyszínen

  • University of South CarolinaCharleston, Egyesült ÁllamokContact: Charlie Strange (principal investigator)Résztvevőt keres
  • University of FloridaGainesville, Egyesült ÁllamokContact: Virginia Clark (principal investigator)Résztvevőt keres
  • Vanderbilt University Medical CenterNashville, Egyesült ÁllamokContact: Suzanne Sharpton (principal investigator)Résztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of AAT, called Z-AAT. Z-AAT builds up in liver cells and also leads to low blood levels of AAT (called Alpha-1 Antitrypsin Deficiency or AATD). Over time, this build up leads to different stages of liver problems, if not treated. This is called natural history of AATD.

A teljes eredeti leírásKevesebb

The main aim of this study is to learn about liver problems caused by AATD in adults when not treated over 4 to 8 years. Other aims are to learn what can predict the AATD-liver condition starting and getting better or worse, describe how this condition is currently being diagnosed and watched in normal care, and describe how the AATD also affects an adult's lung function.

Data in this study will be collected to include medical history of a participant, including the date AATD was first identified and/or the date on which the first AATD-related liver or lung problems were diagnosed. At study start and then every year until study end, participants will be asked to complete questionnaires (called patient-reported outcomes or PROs).

A vizsgálat 2 csoportja

  • Cohort 1: AATD-Pi*ZZ Genotype/Phenotype

    Participants who have been diagnosed with Alpha-1 Antitrypsin Deficiency homozygous ZZ (AATD-Pi\*ZZ) genotype/phenotype with or without liver disease manifestations (fibrosis- F0-F4dc) will be enrolled and data will be prospectively collected per routine care throughout the follow-up period.

  • Cohort 2: AATD-Pi*SZ Genotype/Phenotype

    Participants who have been diagnosed with alpha-1 antitrypsin deficiency heterozygous SZ (AATD-Pi\*SZ) genotype/phenotype with moderate-advanced or severe liver disease (F2-F4dc) manifestations will be enrolled and data will be prospectively collected per routine care throughout the follow-up period.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Prospective Observational Study on the Natural History of Alpha-1 Antitrypsin Deficiency and Associated Liver Disease
A regiszteradat frissítve
2026. július 24.